Mammal skin has a crucial function in several life-preserving processes such as hydration, protection against chemicals and pathogens, initialization of vitamin D synthesis, excretion and heat regulation. Severe damage of the skin may therefore be life-threatening. Skin wound repair is a multiphased, yet well-orchestrated process including the interaction of various cell types, growth factors and cytokines aiming at closure of the skin and preferably resulting in tissue repair. Regardless various therapeutic modalities targeting at enhancing wound healing, the development of novel approaches for this pathology remains a clinical challenge. The time-consuming conservative wound management is mainly restricted to wound repair rather than restitution of the tissue integrity (the so-called “restitutio ad integrum”). Therefore, there is a continued search towards more efficacious wound therapies to reduce health care burden, provide patients with long-term relief and ultimately scarless wound healing. Recent in vivo and in vitro studies on the use of skin wound regenerative therapies provide encouraging results, but more protracted studies will have to determine whether the effect of observed effects are clinically significant and whether regeneration rather than repair can be achieved. For all the aforementioned reasons, this article reviews the emerging field of regenerative skin wound healing in mammals with particular emphasis on growth factor- and stem cell-based therapies.

BackgroundEscherichia coli is bacteria that exist as commensal in the intestine of animals and humans, but pathogenic strains cause disease in chickens. The development of antimicrobial resistance in E. coli is one of major concern worldwide. A cross-sectional study was conducted from November, 2015 to April, 2016 in and around Ambo town on backyard chicken with the objectives of isolating E. coli from selected visceral organs, assessment of potential risk factor and determination of antimicrobial resistance pattern of the isolates.ResultsThe overall isolation rate of E. coli was 11.5% (80/694) [95% CI: 9.64–14.61] and 32.5% (62/191) [95% CI: 25.39–39.09] at organ and chicken level, respectively. E. coli isolation rate was 15.2% (29/191), 13.6% (27/191), 6.3% (12/191) and 10.7% (13/121) from spleen, liver, kidney and ovary samples, respectively. The multivariable logistic regression analysis revealed higher probability of E. coli isolation from adult (adjusted Odds ratio [aOR] =2.5, P = 0.013) than younger chickens, from clinically sick chickens (aOR = 3.0, P = 0.003) than apparently healthy. E. coli isolates were 100% susceptible to ciprofloxacin, norfloxacin and sulfamethoxazole-trimethoprim followed by 89–63.4% susceptibility to gentamicin, streptomycin, ceftazidime, nalidxic acid, nitrofurantoin, kanamycin, amikacin and chloramphenicol. Whereas, 100% resistance was observed against cloxacilin, cefotaxime and amoxicillin, whereas 92.7 and 46.3% were resistant to cefuroxime, and tetracycline, respectively. Multidrug resistant (MDR) was observed in 78.1% (64/82) of the isolates which exhibited 5 different MDR patterns to 7 antimicrobial classes.ConclusionsHigher isolation rate of E. coli was observed from visceral organs of chickens. Age and health status were predictors of E. coli isolation. Remarkable numbers of the isolates are resistant to different antimicrobials and multidrug resistant E coli isolates are widespread in the area.Electronic supplementary materialThe online version of this article (10.1186/s12917-019-1830-z) contains supplementary material, which is available to authorized users.

Staphylococcus aureus is a pathogenic bacterium-contaminating milk and milk products causing food poisoning primarily due to its enterotoxins. The study aimed at estimating the prevalence of S. aureus in milk and milk products, assessing potential risk factors for contamination, and determining the load and the antimicrobial susceptibility profile of the isolates. A cross-sectional study design was employed to collect a total of 486 samples, comprising 383 raw milk, 47 bulk tank milk, 29 curd milk (Ergo), and 28 Ethiopian cottage cheese (Ayib) samples. Enumeration, isolation, and identification of S. aureus were carried out following standard microbiological techniques. Antibiogram was performed using 12 antimicrobials following the Kirby–Bauer disc diffusion method. Logistic regression analyses were used to assess the association between the occurrence of S. aureus in milk and milk products and potential risk factors. The overall prevalence of S. aureus was 10.69% (52/486) [95% confidence interval (CI):8.09–13.79%]. The prevalence of S. aureus in raw milk, curd milk, bulk tanks at the farm, bulk tanks at milk collection facilities, and cottage cheese was 8.64%, 24.14%, 14.73%, 23.08%, and 14.29%, respectively. The rate of isolation of S. aureus was significantly high in curd milk than in other types of samples (P = 0.010). The study revealed that teat washing (OR: 4.93, 95% CI: 2.06–11.81), use of towel (OR: 12.13, 95% CI: 3.74–39.29), and tick infestations (OR: 4.31, 95% CI: 1.28–14.44) were risk factors associated with the occurrence of S. aureus in milk. About 48.39% of the milk samples assessed had the S. aureus count higher than 105 CFU/ml. The highest rate of resistance was observed to ampicillin (95%), amoxicillin (95%), oxacillin (87.5%), and cefotaxime (80%). All isolates are resistant to at least two classes of antimicrobial drugs, while 65.0% of the isolates were found to be multidrug-resistant. The moderate prevalence, high load, and antimicrobial resistance of S. aureus indicate the higher public health risk due to the widespread consumption of raw milk in the area. Good hygienic practices, regular surveillance of antimicrobial resistance, and prudent use of drugs are suggested.

It has been reported that mesenchymal stem cells (MSCs) have homing capacities and immunomodulating effects after an intravenous injection. However, transplanting MSCs in murine tail veins can result in pulmonary reactions and even death of the animals. Unfortunately, only a few intravenous MSC transplantations have been reported in large animal species and these were performed in a limited number of individuals. To assess the safety of MSC transplantations, a large study on 291 recipient horses is reported here. MSCs were isolated from the peripheral blood (PB) of a 4-year-old and 6-year-old donor horse after having tested their PB for a wide range of transmittable diseases. The MSC samples from both donor horses were characterized and resuspended in 1 ml of Dulbecco's Modified Eagle Medium (DMEM) supplemented with 10% Dimethyl Sulfoxide (DMSO). After hand-thawing in the field, 291 horses with ages ranging from 3-months to 33-years were directly injected into their jugular vein. 281 horses (97%) received a single injection of a physiological dose of 0.2 x10(6) MSCs, 5 horses (1.7%) were re-injected after approximately 6 weeks (using the same dose and donor cells) and a single superphysiological dose of 10(6) MSCs was administered to 5 horses as well. In total, 176 recipients were injected with MSCs from the 4-year-old donor and 115 recipients received MSCs from the 6-year-old donor. From all the injected horses (n=291) no acute clinical adverse effects were noticed. Apart from one horse that died of colic 7 months after the treatment, no deaths were registered and all the horses were monitored for 1 year after the injection. In conclusion, no adverse effects were noticed in 291 recipients after an intravenous injection of allogenic PBderived MSCs. Nevertheless, further research is warranted in order to verify the immunogenic properties of these cells after allogenic transplantation into various (patho)physiological sites.